Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors
By G. Kanas, Aliki Taylor, J. Primrose, W. Langeberg, M. Kelsh, F. Mowat, D. Alexander, M. Choti, G. Poston. Clinical Epidemiology, 2012
672 citations recorded by the source corpus.
Background Hepatic metastases develop in approximately 50% of colorectal cancer (CRC) cases. We performed a review and meta-analysis to evaluate survival after resection of CRC liver metastases (CLMs) and estimated the summary effect for seven prognostic factors. Methods Studies published between 1999 and 2010, indexed on Medline, that reported survival after resection of CLMs, were reviewed. Meta-relative risks for survival by prognostic factor were calculated, stratified by study size and annual clinic volume. Cumulative meta-analysis results by annual clinic volume were plotted. Results Five- and 10-year survival ranged from 16% to 74% (median 38%) and 9% to 69% (median 26%), respectively, based on 60 studies. The overall summary median survival time was 3.6 (range: 1.7–7.3) years. Meta-relative risks (95% confidence intervals) by prognostic factor were: node positive primary, 1.6 (1.5–1.7); carcinoembryonic antigen level, 1.9 (1.1–3.2); extrahepatic disease, 1.9 (1.5–2.4); poor tumor grade, 1.9 (1.3–2.7); positive margin, 2.0 (1.7–2.5); >1 liver metastases, 1.6 (1.4–1.8); and >3 cm tumor diameter, 1.5 (1.3–1.8). Cumulative meta-analyses by annual clinic volume suggested improved survival with increasing volume. Conclusion The overall median survival following CLM liver resection was 3.6 years. All seven investigated prognostic factors showed a modest but significant predictive relationship with survival, and certain prognostic factors may prove useful in determining optimal therapeutic options. Due to the increasing complexity of surgical interventions for CLM and the inclusion of patients with higher disease burdens, future studies should consider the potential for selection and referral bias on survival.
Subfields: Hepatology, Oncology, Surgery
View Paper: https://www.semanticscholar.org/paper/a943e3ae89a58516ed9f42a8283ac641fb196a96
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hepatology
In Oncology
Citations in the corpus
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016, background): “However, the concern remains that not all patients with technically resectable liver-limited metastases benefit from surgery, with approximately half developing widespread systemic disease within 3 years of resection [152].”